Drug Profile
Research programme: thrombosis therapy - Bayer/Millennium
Alternative Names: Thrombosis therapy research programme - Bayer/MillenniumLatest Information Update: 03 Feb 2004
Price :
$50
*
At a glance
- Originator Bayer; Millennium Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 27 Jan 2004 Discontinued - Preclinical for Thrombosis in Germany (unspecified route)
- 27 Jan 2004 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
- 31 Oct 2003 Millennium and Bayer have extended their research collaboration